Efficacy of cariprazine on predominant negative symptoms of patients with schizophrenia: post hoc analysis of PANSS data, Marder factors, and cognition

被引：7
|
作者：
Marder, S. [1 ]
Laszlovszky, I. [2 ]
Szalai, E. [2 ]
Szatmari, B. [2 ]
Harsanyi, J. [2 ]
Barabassy, A. [2 ]
Debelle, M. [2 ]
Durgam, S. [3 ]
Bitter, I. [4 ]
Nemeth, G. [2 ]
机构：
[1] Univ Calif Los Angeles, Semel Inst, Sect Psychosis, Los Angeles, CA USA
[2] Gedeon Richter Plc, Med Div, Budapest, Hungary
[3] Forest Res Inst, Clin Dev, Jersey City, NJ USA
[4] Semmelweis Univ, Dept Psychiat & Psychotherapy, Budapest, Hungary
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2016年 / 26卷
关键词：
D O I：
10.1016/S0924-977X(16)31595-4
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.3.d.036
引用
收藏
页码：S550 / S550
页数：1
相关论文
共 50 条
  • [41] What is the minimally clinically important difference in negative symptoms of schizophrenia? PANSS based post hoc analyses of a phase III clinical trial
    Barabassy, A.
    Acsai, K.
    Laszlovszky, I.
    Szatmari, B.
    Harsanyi, J.
    Sebe, B.
    Earley, W.
    Patel, M.
    Nemeth, G.
    EUROPEAN PSYCHIATRY, 2019, 56 : S247 - S247
  • [42] EFFICACY OF LURASIDONE IN THE TREATMENT OF SCHIZOPHRENIA WITH PROMINENT NEGATIVE SYMPTOMS: A POST-HOC ANALYSIS OF SHORT-TERM TRIALS
    Pikalov, Andrei
    Schooler, Nina
    Hsu, Jay
    Cucchiaro, Josephine
    Goldman, Robert
    Loebel, Antony
    SCHIZOPHRENIA RESEARCH, 2014, 153 : S355 - S355
  • [43] Efficacy of Lurasidone in the Treatment of Schizophrenia with Prominent Negative Symptoms: A Post-hoc Analysis of Short-term Trials
    Schooler, Nina R.
    Pikalov, Andrei
    Hsu, Jay
    Cucchiaro, Josephine
    Goldman, Robert
    Loebel, Antony
    NEUROPSYCHOPHARMACOLOGY, 2013, 38 : S513 - S514
  • [44] Efficacy of lurasidone in the treatment of schizophrenia with prominent negative symptoms: A post-hoc analysis of short-term trials
    Schooler, N. R.
    Pikalov, A.
    Hsu, J.
    Cucchiaro, J.
    Goldman, R.
    Loebel, A.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 : 151 - 152
  • [45] The broad efficacy of cariprazine across symptoms in patients with bipolar I disorder: Post hoc analysis of randomized, placebo-controlled trials
    Yatham, Lakshmi
    Vieta, Eduard
    McIntyre, Roger
    Jain, Rakesh
    Earley, Willie
    Patel, Mehul
    BIPOLAR DISORDERS, 2020, 22 : 114 - 114
  • [46] The Effect of Instability of Baseline Severity of Positive Symptoms on End of Treatment Change in the PANSS Negative Factor Score in Negative Symptom Schizophrenia Studies - An Exploratory Post-Hoc Analysis
    Daniel, David
    Wang, Xingmei
    Kott, Alan
    NEUROPSYCHOPHARMACOLOGY, 2021, 46 (SUPPL 1) : 371 - 371
  • [47] Day-to-day and social functioning of patients with negative symptoms of schizophrenia: Post-hoc analyses of a phase 3 clinical trial with cariprazine monotherapy and risperidone
    Barabassy, A.
    Laszlovszky, I.
    Szatmari, B.
    Szalai, E.
    Harsanyi, J.
    Nemeth, G.
    EUROPEAN PSYCHIATRY, 2017, 41 : S270 - S270
  • [48] Monotherapy treatment with cariprazine for the treatment of predominant negative symptoms of patients with schizophrenia: A double-blind, active comparator-controlled trial
    Nemeth, G.
    Debelle, M.
    Laszlovszky, I.
    Szalai, E.
    Szatmari, B.
    Harsanyi, J.
    Barabassy, A.
    Durgam, S.
    Bitter, I.
    Galderisi, S.
    EUROPEAN PSYCHIATRY, 2016, 33 : S256 - S257
  • [49] Adjunctive Cariprazine in Patients With Major Depressive Disorder: Post Hoc Analysis of Efficacy by Baseline Antidepressant Response
    Papakostas, George I.
    Yeung, Paul
    Chen, Chen
    Waraich, Simranpreet
    Kerolous, Majid
    CNS SPECTRUMS, 2023, 28 (02) : 244 - 245
  • [50] EARLY IMPROVEMENT OF PANSS ITEMS IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH BREXPIPRAZOLE: A POST HOC ANALYSIS OF THREE RANDOMIZED STUDIES
    Weiss, Catherine
    Meehan, Stine Rasmussen
    Ouyang, John
    Hobart, Mary
    SCHIZOPHRENIA BULLETIN, 2019, 45 : S296 - S296
12345